Sex differences in stroke: Review of current knowledge and evidence

Abstract

Stroke is a leading cause of death among women in the United States, and women are more affected by stroke than men. With women living longer than men, women experience not only a higher incidence of stroke but also more negative outcomes. Despite its lethal impact and high morbidity rate, the road from innovative bench research to improved clinical outcomes has been slow. This review explores the differential physiology, epidemiology, and clinical presentation of stroke between men and women, as well as the current status of laboratory and clinical data.

Keywords

sex differences stroke women

CME Accreditation Statement

The University of Virginia School of Medicine designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit^TM per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learners are expected to read this article along with any references and supporting material as appropriate, and complete the online post-test questions with an 80% pass rate to receive credit. Post-test questions are accessed through the member portal on the Society for Vascular Medicine (SVM) website (www.vascularmed.org). Please note that CME credits are only available to members of the SVM. This activity expires two years after the publication date, on April 1, 2019.

Disclosures

The faculty, staff and planning committee of the University of Virginia Office of Continuing Medical Education have no financial affiliations to disclose.

The CME planning committee of the Vascular Medicine Editorial Office disclosed the following:

Heather Gornik has disclosed research support from AstraZeneca, intellectual property rights from Summit Doppler Systems, Inc, and intellectual property rights and stock/ownership from FlexLife Health (proceeds donated). Aditya Sharma has disclosed research support from National Institute of Health Sciences, AstraZeneca, Biomet Biologics, Portola Pharmaceuticals, and Pedra Technology. Valerie Clark has no financial affiliations to disclose.

The authors disclosed no financial relationship or interest with any proprietary entity producing healthcare goods or services. These views are not necessarily those of the US Government or the Department of Veteran Affairs.

Introduction

Worldwide, stroke is the third leading cause of death, as well as the leader in long-term disability etiology as of 2012.¹ In the United States specifically, according to the Centers for Disease Control and Prevention, stroke is the fourth leading cause of death, and accounts for 33% of potentially preventable deaths for individuals under 80 years of age between 2008 and 2010.² Notably, 60% of all stroke deaths involve women.³ Population education programs in the last few years, such as the F.A.S.T program and Stroke Awareness Month, have increased the public’s knowledge and awareness of the incidence and impact of stroke in women. Additionally, current research indicates differences in how women and men present with stroke, but also how they are treated in an acute setting and how they respond to treatment methods. These disparities are of vital importance, given that targeted sex-specific therapies can help improve clinical outcomes and reduce the burden of disease in the population. Therefore, this review examines the variations between men and women in risk factors, epidemiology, presentation, treatment, and outcomes of stroke.

Classification and pathophysiology

Strokes are primarily classified as ischemic or hemorrhagic. Ischemic strokes are the most common (87% of all strokes) and occur due to obstruction of a blood vessel supplying the brain. They may be further sub-classified as thrombotic or embolic, depending on the site of occlusion.⁴ Further complicating the classification process is that of cryptogenic stroke, a transient neurological event of obscure or unknown origin, which can account for up to 30% of all strokes, occurs most often in younger patients.⁵ Given that cryptogenic stroke is a transitory event, the etiology is difficult to ascertain, resulting in difficulty selecting definitive treatment.⁶ On the positive side, this category of cerebral infarctions has most often been isolated events with a low recurrence rate and good functional outcomes.⁵ Table 1 highlights these and other stroke subtypes in a number of stroke classification systems. The algorithms vary from study to study, but they are all primarily based on clinical presentation, neurological signs, brain imaging findings, and ancillary testing results. Owing to the differences in methodology, these systems vary in algorithm complexity, equipment required to use them, and the percentage of strokes that fall into the cryptogenic category.

Table 1.

Varying stroke classification systems by western countries.

	TOAST	SSS-TOAST	CCS	ASCOD
Subtypes	LAA CE SVO OD UD	LAA CE SVO OD UD	Supra-aortic LAA CE SVO OD UD	Atherosclerosis CE Small-vessel disease Dissection Other
Significant stenosis degree for diagnosing LAA	>50%	>50% (evident)	>50% Stenosis with plaque ulceration or thrombus <50% at the site of penetrating artery	>50% <50% with endoluminal thrombus Mobile thrombus at aortic arch
Aortic atherosclerosis	Not described	Not described	Cardioembolism	Atherosclerosis
Diameter limitation for SVO	15 mm	20 mm	20 mm	15 mm
Other advantages	Simple Convenient Accurately predicts prognosis	LogicalsReduced prevalence of strokes of undetermined etiology	Web-based Evidence-based Convenient if equipment available	Integration of non-causative factors
Other disadvantages	High prevalence of strokes of undetermined etiology Low validity and reliability in specific subtypes	Complex algorithm	Depends on modern diagnostic tools Needs equipment to connect to website	Difficulty in interpretation Too many subtypes

TOAST, Trials of Org 10172 in Acute ischemic Stroke Treatment; SSS-TOAST, Stop-Stroke Study TOAST; CCS, Causative Classification System; ASCOD, Atherosclerosis, Small vessel disease, Cardiac source, Other cause, Dissection; LAA, large artery atherosclerosis; CE, cardioembolism; SVO, small-vessel occlusion; OD, other determined; UD, undetermined.

Physiologically, ischemic stroke is preceded by endothelial damage in cerebral blood vessels that causes inflammation and fatty deposit accumulation in arterial walls. The subsequent decrease in blood vessel diameter and vascular flow causes hypoxic and hypoglycemic conditions in the brain tissue, resulting in an ischemic core (blood flow < 10 mL/100 mg/min) and an ischemic penumbra (blood flow > 10, but less than 20 mL/100 mg/min).^7,8 Neurons have significant functional loss in hypoxia-ischemia, as evidenced by the decreased adenosine triphosphate (ATP) production in the ischemic core neurons, thereby activating the ischemic cascade. The membrane ionic gradient is lost, leading to intracellular sodium and calcium increases; subsequent glutamate release further increases calcium influx via NMDA and AMPA receptors.⁹ The resulting excitotoxicity leads to organelle and membrane swelling, loss of integrity, and ultimately necrosis.⁸ In the ischemic penumbra, however, decrease in blood flow alone is not capable of inducing neuronal necrosis, but is sufficient to create an environment vulnerable to further insult. Ultimately, the adjacent ischemic core glutamate production leads to intracellular calcium accrual in the penumbra. This activates cellular enzymes such as calcium-dependent calpains and caspases, endonucleases, proteases and ATPases, causing increases in nitric oxide, arachidonic acid, and superoxide radicals that help cells die.^8–12

In contrast, hemorrhagic strokes (13% of all strokes) are intracerebral or subarachnoid in nature and occur due to ruptured vessels.¹³ Although less common than ischemic strokes, hemorrhagic strokes are more fatal to patients due to potential hydrocephalus, increased intracranial pressure, and blood vessel spasms.^14,15 With regards to incidence, men are more likely to have ischemic strokes,¹⁶ while women are at greater risk for subarachnoid hemorrhage.¹⁷ These strokes are typically associated with chronic hypertension and/or vascular malformations, both of which may lead to vessel wall weakening or aneurysmal degeneration with rupture.

Blood build-up in the subarachnoid space or brain tissue can lead to infarction as well as brain tissue and vascular toxicity.¹⁸

Before concluding this section, we will briefly touch on other causes of stroke, as they pertain to the scope of this review. Other arterial causes of acute ischemic stroke which are more common in women include fibromuscular dysplasia (FMD) and carotid dissection.^19,20 These two entities may be found separately or be associated. Fibromuscular dysplasia is a non-atherosclerotic, non-inflammatory disease process of the blood vessels that can result in arterial stenosis, occlusion, aneurysm, or dissection.^21,22 The etiology of FMD and its prevalence in the general population are not well understood, as the symptoms are non-specific and the disease is poorly understood. Studies have shown that women are affected more than men, in a 9:1 ratio.²³ Treatment for FMD may include medical therapy, surveillance, endovascular intervention, and surgery. Additionally, carotid dissection may occur in the setting of FMD, but also during pregnancy and the puerperium.²⁴ Internal carotid artery dissection, which may occur intracranially or extracranially, can also be spontaneous or associated with major or minor trauma. Any spontaneous dissection may have an association with a genetic, familial, or heritable disorder. A full discussion of these lesser occurring vascular diseases is beyond the scope of this review.

Finally, a relatively rare vascular disorder that is more prevalent in women is cerebral venous and sinus thrombosis.^25,26 This subtype of stroke is more common in younger to middle-aged women (3:1 ratio women to men). The main sex-specific risk factor attributed to this differential incidence is oral contraceptive use. Women tend to develop an underlying thrombophilia, warranting routine testing. Generally, though, outcomes are excellent, a stark contrast from those seen in arterial strokes.²⁶

Epidemiology

Current population data indicates that 16.9 million individuals suffer from stroke yearly, equating to a global incidence of 258 per 100,000 per year.²⁷ Historically, from 1970 to 2008, population data indicates that in high-income countries, stroke events have decreased by 42%; in contrast, in low and middle-income nations, stroke incidence has increased over 100%.²⁸ However, even in nations with stroke incidence decline, the lifetime risk reduction is not proportional, and tends to be greater for men (19.5% to 14.5%) than women (18.0% to 16.1%).²⁹ Furthermore, as women age, they demonstrate greater risk than age-matched men due to mid-life stroke surges.³⁰ This is reflected in male-female incidence rate ratios decreasing from 1.49 (ages 35–44) to 1.21 (ages 75–84).³¹

Women have higher lifetime stroke risk and have been found to have recurrent strokes more frequently than men.³ This is partially explained by women’s greater life expectancy and that age is a non-adjustable risk factor; therefore, more women are living to ages where stroke risk is higher. Furthermore, women also have higher mortality rates from stroke than men.³² A potential explanation for this trend is that the mean age of first stroke for men is 68.6 years, while it is 72.9 years for women.³¹ According to the Centers for Disease Control and Prevention, men and women under the age of 45 have similar stroke mortality rates.³³ From this age on, women’s stroke mortality rate increases significantly, and although their rate is lower than age-matched men, the difference decreases with age.³⁴ A plausible explanation for this occurrence is the neuroprotective loss of estrogen post-menopausal women experience.^35,36

These findings are qualitatively reflected in Table 2 and Figure 1. In Table 2, note that females over 20 years old have greater prevalence of stroke when compared to males (600,000 more cases annually but only 2.7% compared to 2.6% for men). However, it is instructive to note that females at all ages have far higher rates of new and recurrent attacks at all ages (53.5% vs 46.5% for men), higher mortality (58.4% vs 41.6% for men), and a greater number of discharges (530,000 to 485,000), indicating the effect it has on women. Furthermore, African Americans almost double the rates of prevalence in Caucasians; in both black and white individuals, women have greater rates of stroke. Finally, in Figure 1, we can see that regardless of race, younger women have fewer strokes than age-matched males. However, once women pass menopause, their rates of stroke are far greater than male rates, thus explaining the overall prevalence rates seen in Table 2.

Table 2.

Stroke incidence in various populations (2012 data).

Population group	Prevalence Age ⩾ 20 years	New and recurrent strokes All ages
Both sexes	6,600,000 (2.6%)	795,000
Males	3,000,000 (2.6%)	370,000 (46.5%)^a
Females	3,600,000 (2.7%)	425,000 (53.5%)^a
NH white males	2.2%	325,000^b
NH white females	2.5%	365,000^b
NH black males	4.2%	45,000^b
NH black females	4.7%	60,000^b
Hispanic males	2.8%	–
Hispanic females	2.0%	–

NH, non-Hispanic.

These percentages represent the portion of total stroke incidence that applies to males vs females.

Estimates include Hispanics and non-Hispanics. Estimates for white individuals include other non-black races.

Figure 1.

Risk factors

Risk factor differences between men and women in part account for epidemiological findings in stroke incidence, prevalence, and mortality. A number of sex-non-specific modifiable risk factors exist, including atrial fibrillation and other cardiac conditions, hypertension, cigarette smoke exposure, alcohol consumption, physical inactivity, metabolic syndrome, and Type 2 diabetes mellitus.^37,38 Non-modifiable risk factors exist as well, such as age (stroke rate doubles every 10 years after age 55), sex, family history, and being of African American descent.^34,39,40 Figure 2 demonstrates the increase in the 10-year stroke rate for adult men and women as the number of comorbid conditions increases. Interestingly, women have lower 10-year rates of stroke without comorbidities, but a greater rate with four or more, implying that their stroke risk is more affected than in men.

Figure 2.

Stroke risk by number of comorbidities. (AF, atrial fibrillation; CVD, cardiovascular disease.) Republished with permission of Wolters Kluwer Health, Inc., from ref. 3; Copyright © 2015, American Heart Association, Inc.; Reproduced with permission.

Many of the aforementioned modifiable risk factors are more common in males, but when considering only stroke patients, they are shown to increase stroke risk more in females (as noted in discussion of Figure 2). For example, while hypertension and atrial fibrillation are more common in men than pre-menopausal women,⁴¹ females with these conditions have a greater stroke risk.^42,43 Similarly, Type 2 diabetes mellitus more often presents in men with stroke;⁴⁴ again, the condition has a greater effect on increasing stroke risk in women.⁴⁵ With respect to metabolic syndrome, its presence doubled ischemic stroke risk in women, but had no statistically significant effect on men.⁴⁶

Sex-specific risk factors must be considered as well. For men, the most significant are alcohol and tobacco use, myocardial infarction history, and peripheral arterial disease.⁴² Furthermore, reduced total testosterone levels in circulation have been associated with increased stroke incidence for men even after adjusting for common risk factors in cardiovascular disease.⁴⁷ Although the pathophysiological connection between testosterone and stroke occurrence is unclear, low testosterone levels have been linked to metabolic syndrome, Type 2 diabetes mellitus, and aortic arterial disease, which are all independent stroke risk factors.⁴⁸ With respect to women, the use of oral contraceptives is linked to increased risk of ischemic stroke, potentially due to the hypercoagulable states that are induced.⁴⁹ Similarly, pregnancy-related effects on hemodynamics (increases in pro-coagulant activity in maternal blood, decreases in anti-coagulant factors, and impaired fibrinolytic activity) predispose women to stroke.⁵⁰ Furthermore, menopause has been linked to metabolic syndrome onset⁵¹ and increased blood pressure,⁴¹ which have been theorized to be caused by drops in estrogen levels.

While most studies have focused on risk factors for stroke, the GIFA study assessed a cohort of older adults to ascertain prognostic variables for cognitive impairment, disability at discharge, and in-hospital mortality rates following acute cerebrovascular events: 52% were women in this robust dataset, but more than 50% of the patients enrolled with acute stroke were also female. Therefore their analysis noted that there was no difference associated with female sex and functional status or mortality after an acute stroke event.⁵²

Sex-steroid hormones

The menopause-related loss of estrogen’s neuroprotective effects sheds some light as to why there is a mid-life surge in stroke incidence in post-menopausal women. High levels of 17-β estradiol (E2) have been found to attenuate stroke effects in pre-menopausal women.⁵³ Estrogen binds vascular smooth muscle and endothelial receptors,⁵⁴ thus facilitating vasodilation through a number of pathways.^53,55 Nitric oxide specifically regulates myogenic tone in cerebral vessel autoregulation to shield against blood flow fluctuations that can cause vessel damage and rupture.⁵⁵ Overall, blood supply in pre-menopausal women is better than in men during and after ischemic stroke, leading to lower infarct volumes.

Several studies have also demonstrated that 17-β estradiol directly influences neuronal cell survival in stroke. Specifically, it has been demonstrated that physiological levels of E2 inhibited injury-induced downregulation of bcl-2, resulting in increased cerebral cortex neuronal survival.⁵⁶ Furthermore, in middle cerebral artery occlusion, E2 has been shown to attenuate apoptosis processes such as caspase-3 activation, DNA fragmentation, and Akt kinase activation.⁵⁷ It is clear that estrogen plays a critical role in stroke outcomes, reducing infarct severity and regulating vascular tone.

Progesterone receptors also exist on vascular smooth muscle and endothelial cells,^58,59 and their activation serves two functions. First, it decreases inflammation,⁶⁰ edema,⁶¹ and oxidative stress,⁶² subsequently leading to reduced cortical infarct. Second, they inhibit vascular smooth muscle proliferation, which is essential for atherogenesis.⁶³ In animal trials, micronized progestin has been shown to decrease stroke lesion volume; however, it also increased mortality after experimental stroke.⁶⁴ Future research conducted to ascertain the exact steroid-mediated mechanisms must consider factors such as timing of hormone exposure relative to menopause, differences in hormone preparation, and intrinsic stroke susceptibility to determine the viability of hormone replacement therapy.

Insulin-like growth factor (IGF), although not sex-specific in production levels, is similar to estrogen in the conferring of neuroprotective effects. The IGF system mediates a variety of anabolic and somatogenic effects and is produced by a myriad of cell types.⁶⁵ With respect to stroke, increased IGF levels have been connected to experimental hypoxic injury in areas of neuronal loss; specifically, microglia and astrocytes show increased post-ischemic production of IGF-1.⁶⁶ Low endogenous levels of IGF-1 have been also associated with increased stroke mortality.⁶⁷ More recently, studies on aging female rats have shown the neuroprotective post-stroke effect of IGF-1 treatment, which may reduce infarct volume,^68,69 reduce cytokines and chemokines, and improve the blood–brain barrier stability.⁷⁰ Thus, the age-dependent decline of IGF-1 in middle-aged females⁷¹ in conjunction with post-menopausal estrogen level drops may further serve to explain the stroke incidence and severity seen in older females.⁷²

Differential symptom presentation and associated treatment delays

Population-level studies on sex differences in stroke presentation have been limited. Available studies indicate that women display generalized symptoms more than men do, often presenting with non-traditional signs.⁷³ For example, in ischemic stroke, women more often have disorientation, generalized weakness, mental status changes,⁷⁴ headache, pain, and changes in consciousness.⁷⁵ Furthermore, women have been found to present with urinary incontinence, visual deficits such as diplopia, and dysphasia.⁴² On the other hand, men more commonly present with nystagmus and sensory abnormalities.⁷⁴ These findings are relevant because they impact the treatment methods care providers choose; in turn, this affects patient outcomes.

As with symptomatic presentation differences between men and women, there has been minimal conclusive research on the effect of symptomatic presentation differences on pre-hospital delays between men and women. Various studies have noted that women arrive later than men,^76–80 that women arrive sooner than men,^81,82 and that there is no significant difference.⁸³ The reasons for these arrival time delays have been attributed to sex,⁸² with studies noting that it may be in part due to women presenting with more non-traditional signs, which could account for greater delays in arrival to the emergency department and potential misdiagnosis.

According to many studies though, women are significantly older than men at stroke onset³¹ and, thus, are more likely to be living alone or in an institution during a stroke episode.⁸⁴ Given that the response of nearby individuals is a key element in reducing delay time,⁷⁹ it is evident that living alone is thus positively correlated with increased pre-hospital delays.⁸⁵ As of now, a consensus has not been reached regarding if there are sex-dependent delays, and if they do exist, what are the reasons behind these delays. Nevertheless, it is evident that further research is necessary. In the meantime, healthcare providers must be aware of potential differences between men and women in order to choose appropriate treatment methods.

Treatment modalities

Hospital-based studies have been inconclusive as to ascertaining whether or not sex-dependent differences exist in the use of certain treatments. More convincing is the evidence that has been found regarding sex-dependent treatment effectiveness in women and men. With respect to frequency of use, women have been found to be less likely to get brain imaging, Doppler examination, echocardiograms, and angiography than age-adjusted men.⁴² Another study found similar discrepancies in diagnostic procedures ordered for men and women, where women were less likely to receive echocardiography, angiography, cardiac monitoring, and lipid investigation; however, age-adjusted analyses found these differences to be insignificant except in the case of lipid investigation.⁸⁶

Carotid procedures are performed at very high rates in the United States. Carotid stenting has become an increasingly popular choice over carotid endarterectomy (CEA) in high-risk individuals; as noted in Figure 3, CEA rates continue to drop. Regarding interventions for carotid stenosis specifically, some of the recent trials comparing CEA and carotid artery stenting (CAS) have demonstrated sex-specific outcome variances. For example, carotid endarterectomy is performed less in women than in men, even after adjusting for age and comorbidity.⁸⁷ This conclusion is debated by other studies though, given that variation has been attributed to higher perioperative risk in women.⁸⁸ In addition, the disparity may be that men simply have a greater prevalence of carotid artery disease.⁸⁹ One study specifically found that when counting only procedures done for confirmed carotid artery occlusive disease, the differences between rates of CEA were negligible between the sexes.⁹⁰ Overall, men do tend to benefit more, given that only women and men with higher than 70% symptomatic stenosis receive similar long-term benefits.⁸⁸ Furthermore, in women without stroke risk factors other than carotid artery stenosis, CEA was not beneficial for women with 50–69% stenosis.⁸⁸ This finding may also explain why care providers may choose not to use the therapy as frequently in women, especially for those with less than a high-grade stenosis.⁸⁸

Figure 3.

Rates of carotid endarterectomy versus carotid artery stenting. Republished with permission of Wolters Kluwer Health, Inc., from ref. 3; Copyright © 2015, American Heart Association, Inc.; Reproduced with permission.

In the recent prospective randomized trial Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), sex differences were examined.⁹¹ This robust trial found that the periprocedural risk of events was higher in women who underwent CAS compared to CEA, whereas there was little difference seen in outcomes among men. Whether or not this difference was due to differential decision-making remains to be studied. In a very recent study utilizing the Agency for Healthcare Research and Quality National Inpatient Sample and State Ambulatory Services Databases, 1.7 million patients who underwent CAS or CEA over a 14-year time frame were analyzed.⁹² A major finding was that for risk-matched patients, with both asymptomatic and symptomatic carotid disease undergoing CAS, female sex was an important variable associated with worse outcomes including higher stroke risk and inpatient mortality. Conversely, women, as well as men, undergoing CEA in this study had superior outcomes. Therefore, more work is needed to identify specific populations who will benefit from carotid intervention and why, exactly, do sex differences exist.

Some therapies are offered at similar rates to both men and women, but differences exist in the benefits conferred. For example, men benefit more than women in stroke unit care even after shorter stays.⁹³ Furthermore, although men and women are admitted to rehabilitation centers at equivalent rates, women have reduced functional recovery after stroke.⁹⁴ Additionally, stroke-related medication has been ascertained to be used less frequently in women.³⁴ Surprisingly, though, aspirin reduced ischemic stroke risk in women, but had minimal effects in men.⁹⁵ The exact underlying mechanism for this finding has not been determined, but one study indicates that it is due to sex hormone interaction with thrombosis.⁹⁶ Similar to aspirin, warfarin treatment was found to be lower in women upon admission and at discharge.⁸⁴ Nevertheless, warfarin treatment for women with atrial fibrillation-induced stroke showed greater risk reduction than in men.⁹³

While the aforementioned treatments are utilized, the only FDA-approved therapy for stroke is intravenous (IV) recombinant tissue plasminogen activator (rt-PA).⁹⁷ However, thrombolytics have been used at different rates based on sex. One large, retrospective study performed in a community hospital noted that male sex increased the likelihood of IV rt-PA usage.⁹⁸ These findings are alarming when considered in conjunction with epidemiological findings that stroke incidence in women is higher than in men. More concerning is that, with respect to IV rt-PA treatment differences, the primary reason for non-treatment was delayed presentation.⁹⁹ Given that women also have a greater likelihood to display diffuse non-specific symptoms, live alone, receive different diagnostic procedures, and experience significant delays in obtaining care in the hospital, this further reduces the possibility of them getting appropriate and timely care.

Therefore, future research needs to focus on developing treatments that are both effective in women and have longer therapeutic windows, given the potential delays in presentation for women. This is particularly important for preclinical studies as well, where novel neuroprotectants are initially tested. Recent studies using experimental models show that candidate compounds may be neuroprotective for stroke in one sex and not the other, as in the case of nitric oxide and poly(ADP-ribose) polymerase (PARP) inhibitors,¹⁰⁰ which are protective for stroke in males but not females, or caspase inhibition¹⁰¹ or anti-Let7f,¹⁰² which are protective in females but not males. Inclusion of clinically valid characteristics in experimental studies such as age, sex, and other comorbid disease will increase the likelihood of discovering effective stroke drugs.

Stroke outcomes

Post-stroke outcomes are poorer for women than for men. However, care must be taken in reviewing outcomes studies due to the variety of confounding variables that may be present. These include but are not limited to pre-stroke functionality, social support, demographics, and living conditions. On average, women experience more severe strokes¹⁰³ and have longer hospitals stays.¹⁰⁴ As a result, they have higher stroke-related mortality.¹⁰⁴ If they do survive the initial event, a higher percentage of women than men remain permanently disabled.¹⁰⁵

Consequently, this results in lower post-stroke quality of life. A stroke-specific quality of life scale measuring physical functional levels found that women scored lower than men.⁷³ Stroke-related outcomes also include reductions in mental health, and it has been shown that women are more likely to have post-stroke depression than men.¹⁰⁶ It should be noted that this may be ascribed to decreased social support, considering that women are more isolated than men at older ages. Nevertheless, this is a critical issue given that depression has been found to increase mortality,¹⁰⁷ decrease functional recovery,¹⁰⁸ and considerably undermine quality of life.¹⁰⁹

These changes can, in part, explain the reduced quality of life that women experience. The fact that women also more frequently require assistance with activities of daily living further contributes to understanding the quality of life scores. One study found that women had reduced odds, compared to men, of achieving activity of daily life independence 3 months after being discharged. Interestingly, these differences were not due to age at which stroke occurred or other clinical traits.⁷³ Supporting this research, another group found that women were more likely to be disabled, single, and in an assisted living home than men were 3–6 months after stroke.¹¹⁰ These studies serve as strong evidence as to why women have higher dependency after strokes and more discharges to nursing homes.¹¹¹

Conclusions

Current research, albeit significant in the absolute number of studies, is still lacking based on the controversial and conflicting findings. The data are fairly solid and consistent regarding the epidemiology and outcomes of stroke in men and women, with women facing greater rates of stroke at older ages and worse outcomes. However, much work remains to be done in the identification of how men and women present differently following a stroke, both with regards to symptoms and signs as well as to presentation times. Table 3 summarizes the major salient findings in this review along with specific references supporting these results. Furthermore, research needs to focus on the differential response of care providers based on the sex of the patient, and how it can be standardized to offer equivalent levels of care. Finally, more research is needed to determine if and how sex-specific steroids confer neuroprotection against stroke. These topics are essential to understanding the differences identified in stroke outcomes for women and men.

Table 3.

Summary of Sex Differences in Stroke.

Category	Differences	References
Epidemiology	• A 50 year study (1950-2004) showed greater declines in lifetime-risk at age 65 in men than in women (19.4% to 14.5% vs. 18.0% to 16.1)	29
	• Aging affects stroke incidence in females more than in males; male-female incidence rate ratios changed from 1.49 (ages 35-44) to 1.21 (ages 75-84)	31
	• Mortality rates are higher for women than for men	32
Risk Factors	• Hypertension, atrial fibrillation, and type 2 diabetes mellitus occur more in men, but women with the comorbidities demonstrate higher stroke risk	41, 42, 43, 44, 45
	• Metabolic syndrome doubles ischemic stroke risk in women, but has no effect on men’s risk	46
	• Low testosterone in males is linked to metabolic syndrome, type 2 diabetes mellitus, and aortic arterial disease, all independent stroke risk factors	47, 48
	• Oral contraceptive pills, pregnancy, and menopause are linked to increased stroke rates in women	49, 50, 51
Symptoms	• Women present with more atypical symptoms, such as disorientation, weakness, mental status changes, headache, pain, changes in consciousness, urinary incontinence, diplopia, and dysphagia	42, 73, 74, 75
	• Men have more typical symptoms, such as slurred speech and facial droop, as well as nystagmus, and sensory abnormalities	42, 74
Treatment Modalities	• Use rate differences of brain imaging, Doppler examination, echocardiograms, angiography, and lipid investigations between age-adjusted men and women is debated	42, 86
	• Carotid endarterectomy (CEA) is less used in women than in age- and comorbidity-matched men. This has largely been attributed to greater perioperative surgical danger in women and greater prevalence of carotid artery disease in men	87, 88, 89, 90
	• Carotid stenting has worse outcomes, higher stroke risk, and greater inpatient mortality rates for women	92
	• IV tissue plasminogen activator is more often used in men than women	98
Outcomes	• Long-term surgical CEA outcomes are better for men when there is greater than 70% stenosis; CEA for women with 50-69% stenosis was not beneficial	88
	• Women experience more severe strokes, have longer hospital stays, and a greater percentage remain permanently disabled	103, 104, 105
	• Women have greater rates of post-stroke depression, leading to increased mortality, decreased functional recovery, and decreased quality of life	106, 107, 108, 109
	• Women are less able to achieve daily independence 3 months after discharge and have greater rates of discharge to nursing homes, regardless of age when stroke occurred	73, 111

References

Samai

Martin-Schild

. Sex differences in predictors of ischemic stroke: Current perspectives. Vasc Health Risk Manag 2015; 11: 427–436.

Yoon

Bastian

Anderson

. Potentially preventable deaths from the five leading causes of death—United States, 2008–2010. Morb Mortal Wkly Rep 2014; 63: 369–374.

Mozaffarian

Benjamin

. Heart Disease and Stroke Statistics—2016 Update: A Report from the American Heart Association. Circulation 2016; 133: e38–360.

Donnan

Fisher

Macleod

. Stroke. Lancet 2008; 371: 1612–1623.

Arauz

Merlos-Benitez

Roa

. Cryptogenic stroke in young patients: Long-term prognosis and recurrence. Neurologia 2011; 26: 279–284.

Kisialiou

Grella

Carrizzo

. Risk factors and acute ischemic stroke subtypes. J Neurol Sci 2014; 339: 41–46.

Moskowitz

Iadecola

. The science of stroke: Mechanisms in search of treatments. Neuron 2010; 67: 181–198.

Lipton

. Ischemic cell death in brain neurons. Physiol Rev 1999; 79: 1431–1568.

Ankarcrona

Dypbukt

Bonfoco

. Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15: 961–973.

10.

Dirnagl

Iadecola

Moskowitz

. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999; 22: 391–397.

11.

Dalkara

Moskowitz

. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399–415.

12.

Katsuki

Okuda

. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 1995; 46: 607–636.

13.

Amarenco

Bogousslavsky

Caplan

. Classification of stroke subtypes. Cerebrovasc Dis 2009; 27: 493–501.

14.

Demirgil

Tugcu

Postalci

. Factors leading to hydrocephalus after aneurysmal subarachnoid hemorrhage. Minim Invasive Neurosurg 2003; 46: 344–348.

15.

Zoerle

Lombardo

Colombo

. Intracranial pressure after subarachnoid hemorrhage. Crit Care Med 2015; 43: 168–176.

16.

Petty

Brown

Jr Whisnant

. Ischemic stroke subtypes: A population-based study of incidence and risk factors. Stroke 1999; 30: 2513–2516.

17.

Sacco

. Stroke risk factors: An overview. In: Norris

Hachinkski

(eds) Stroke Prevention. New York: Oxford University Press, 2001, pp.17–42.

18.

Van Gijn

Rinkel

. Subarachnoid haemorrhage: Diagnosis, causes and management. Brain 2001; 124: 249–278.

19.

Schievink

Roiter

. Epidemiology of cervical artery dissection. Front Neurol Neurosci 2005; 20: 12–15.

20.

Kim

Serhal

. The diagnosis and treatment of fibromuscular dysplasia: An update for cardiologists. Curr Treat Options Cardiovasc Med 2016; 18: 37.

21.

Olin

Gornik

Bacharach

. Fibromuscular dysplasia: State of the science and critical unanswered questions: A scientific statement from the American Heart Association. Circulation 2014; 129: 1048–1078.

22.

Kim

Olin

Froehlich

. Clinical manifestations of fibromuscular dysplasia vary by patient sex: A report of the United States Registry for Fibromuscular Dysplasia. J Am Coll Cardiol 2013; 62: 2026–2028.

23.

Olin

Froehlich

. The United States Registry for Fibromuscular Dysplasia: Results in the first 447 patients. Circulation 2012; 125: 3182–3190.

24.

Reinhard

Munz

von Kannen

. Risk of recurrent cervical artery dissection during pregnancy, childbirth and puerperium. Eur J Neurol 2015; 22: 736–739.

25.

Buchanan

Brazinsky

. Dural sinus and cerebral venous thrombosis. Incidence in young women receiving oral contraceptives. Arch Neurol 1970; 22: 440–444.

26.

Coutinho

Ferro

Canhao

. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40: 2356–2361.

27.

Bejot

Daubail

Giroud

. Epidemiology of stroke and transient ischemic attacks: Current knowledge and perspectives. Rev Neurol (Paris) 2016; 172: 59–68.

28.

Feigin

Lawes

Bennett

. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. Lancet Neurol 2009; 8: 355–369.

29.

Carandang

Seshadri

Beiser

. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 2006; 296: 2939–2946.

30.

Towfighi

Saver

Engelhardt

. A midlife stroke surge among women in the United States. Neurology 2007; 69: 1898–1904.

31.

Appelros

Stegmayr

Terent

. Sex differences in stroke epidemiology: A systematic review. Stroke 2009; 40: 1082–1090.

32.

West

Cole

Goodkind

. 65+ in the United States: 2010. US Census Bureau, https://www.census.gov/content/dam/Census/library/publications/2014/demo/p23-212.pdf (2014, accessed 7 January 2016).

33.

Centers for Disease Control and Prevention. Interactive Atlas of Heart Disease and Stroke. U.S. Department of Health & Human Services, http://nccd.cdc.gov/dhdspatlas/ (accessed 7 January 2016).

34.

Reeves

Bushnell

Howard

. Sex differences in stroke: Epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008; 7: 915–926.

35.

Lisabeth

Bushnell

. Menopause and stroke: An epidemiologic review. Lancet Neurol 2012; 11: 82–91.

36.

Hurn

Brass

. Estrogen and stroke: A balanced analysis. Stroke 2003; 34: 338–341.

37.

Romero

Morris

Pikula

. Stroke prevention: Modifying risk factors. Ther Adv Cardiovasc Dis 2008; 2: 287–303.

38.

Aoki

Uchino

. Treatment of risk factors to prevent stroke. Neurotherapeutics 2011; 8: 463–474.

39.

Wolf

D’Agostino

O’Neal

. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992; 23: 1551–1555.

40.

Howard

Anderson

Sorlie

. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke 1994; 25: 2120–2125.

41.

Coylewright

Reckelhoff

Ouyang

. Menopause and hypertension: An age-old debate. Hypertension 2008; 51: 952–959.

42.

Di Carlo

Lamassa

Baldereschi

. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: Data from a multicenter multinational hospital-based registry. Stroke 2003; 34: 1114–1119.

43.

Stewart

Hart

Hole

. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359–364.

44.

Kissela

Khoury

Kleindorfer

. Epidemiology of ischemic stroke in patients with diabetes: The greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355–359.

45.

Peters

Huxley

Woodward

. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014; 383: 1973–1980.

46.

Galassi

Reynolds

. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006; 119: 812–819.

47.

Yeap

Hyde

Almeida

. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353–2359.

48.

Laaksonen

Niskanen

Punnonen

. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041.

49.

Kemmeren

Tanis

van den Bosch

. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202–1208.

50.

Brenner

. Haemostatic changes in pregnancy. Thromb Res 2004; 114: 409–414.

51.

Jouyandeh

Nayebzadeh

Qorbani

. Metabolic syndrome and menopause. J Diabetes Metab Disord 2013; 12: 1.

52.

Tuttolomondo

Pedone

Pinto

. Predictors of outcome in acute ischemic cerebrovascular syndromes: The GIFA study. Int J Cardiol 2008; 125: 391–396.

53.

Krause

Duckles

Pelligrino

. Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol (1985) 2006; 101: 1252–1261.

54.

Farhat

Lavigne

Ramwell

. The vascular protective effects of estrogen. FASEB J 1996; 10: 615–624.

55.

Geary

Krause

Duckles

. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 2000; 279: H511–519.

56.

Dubal

Shughrue

Wilson

. Estradiol modulates bcl-2 in cerebral ischemia: A potential role for estrogen receptors. J Neurosci 1999; 19: 6385–6393.

57.

Rau

Dubal

Bottner

. Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 2003; 23: 11,420–11,426.

58.

Nakamura

Suzuki

Inoue

. Progesterone receptor subtypes in vascular smooth muscle cells of human aorta. Endocr J 2005; 52: 245–252.

59.

Welter

Hansen

Saner

. Membrane-bound progesterone receptor expression in human aortic endothelial cells. J Histochem Cytochem 2003; 51: 1049–1055.

60.

Gibson

Constantin

Prior

. Progesterone suppresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp Neurol 2005; 193: 522–530.

61.

Wang

Jiang

Liu

. Neuroprotective effects of progesterone following stroke in aged rats. Behav Brain Res 2010; 209: 119–122.

62.

Ozacmak

Sayan

. The effects of 17β estradiol, 17α estradiol and progesterone on oxidative stress biomarkers in ovariectomized female rat brain subjected to global cerebral ischemia. Physiol Res 2009; 58: 909–912.

63.

Morey

Pedram

Razandi

. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 1997; 138: 3330–3339.

64.

Wong

Renton

Gibson

. Progesterone treatment for experimental stroke: An individual animal meta-analysis. J Cereb Blood Flow Metab 2013; 33: 1362–1372.

65.

Jones

Clemmons

. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3–34.

66.

Gluckman

Klempt

Guan

. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun 1992; 182: 593–599.

67.

Laughlin

Barrett-Connor

Criqui

. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: The Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89: 114–120.

68.

Selvamani

Sohrabji

. The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. J Neurosci 2010; 30: 6852–6861.

69.

Bake

Selvamani

Cherry

. Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for middle-aged female rats. PLoS One 2014; 9: e91427.

70.

Bake

Okoreeh

Alaniz

. Insulin-like growth factor (IGF)-I modulates endothelial blood-brain barrier function in ischemic middle-aged female rats. Endocrinology 2016; 157: 61–69.

71.

Bartke

. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: Novel findings. Aging Cell 2008; 7: 285–290.

72.

Sohrabji

. Estrogen-IGF-1 interactions in neuroprotection: Ischemic stroke as a case study. Front Neuroendocrinol 2015; 36: 1–14.

73.

Gargano

Reeves

; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators. Sex differences in stroke recovery and stroke-specific quality of life: Results from a statewide stroke registry. Stroke 2007; 38: 2541–2548.

74.

Jerath

Reddy

Freeman

. Gender differences in presenting signs and symptoms of acute ischemic stroke: A population-based study. Gend Med 2011; 8: 312–319.

75.

Labiche

Chan

Saldin

. Sex and acute stroke presentation. Ann Emerg Med 2002; 40: 453–460.

76.

Smith

Lisabeth

Bonikowski

. The role of ethnicity, sex, and language on delay to hospital arrival for acute ischemic stroke. Stroke 2010; 41: 905–909.

77.

Menon

Pandey

Morgenstern

. Critical factors determining access to acute stroke care. Neurology 1998; 51: 427–432.

78.

Mandelzweig

Goldbourt

Boyko

. Perceptual, social, and behavioral factors associated with delays in seeking medical care in patients with symptoms of acute stroke. Stroke 2006; 37: 1248–1253.

79.

Barr

McKinley

O’Brien

. Patient recognition of and response to symptoms of TIA or stroke. Neuroepidemiology 2006; 26: 168–175.

80.

Cheung

. Hong Kong patients’ knowledge of stroke does not influence time-to-hospital presentation. J Clin Neurosci 2001; 8: 311–314.

81.

Nowacki

Nowik

Bajer-Czajkowska

. Patients’ and bystanders’ awareness of stroke and pre-hospital delay after stroke onset: Perspectives for thrombolysis in West Pomerania Province, Poland. Eur Neurol 2007; 58: 159–165.

82.

Lacy

Suh

Bueno

. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 2001; 32: 63–69.

83.

Derex

Adeleine

Nighoghossian

. Factors influencing early admission in a French stroke unit. Stroke 2002; 33: 153–159.

84.

Glader

Stegmayr

Norrving

. Sex differences in management and outcome after stroke: A Swedish national perspective. Stroke 2003; 34: 1970–1975.

85.

Rossnagel

Jungehulsing

Nolte

. Out-of-hospital delays in patients with acute stroke. Ann Emerg Med 2004; 44: 476–483.

86.

Gargano

Wehner

Reeves

. Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008; 39: 24–29.

87.

Kapral

Redelmeier

. Carotid endarterectomy for women and men. J Womens Health Gend Based Med 2000; 9: 987–994.

88.

Alamowitch

Eliasziw

Barnett

. The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke 2005; 36: 27–31.

89.

Mathiesen

Joakimsen

Bonaa

. Prevalence of and risk factors associated with carotid artery stenosis: The Tromsø Study. Cerebrovasc Dis 2001; 12: 44–51.

90.

Patrick

Concato

Viscoli

. Sex differences in the management of patients hospitalized with ischemic cerebrovascular disease. Stroke 1995; 26: 577–580.

91.

Howard

Lutsep

Mackey

. Influence of sex on outcomes of stenting versus endarterectomy: A subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Lancet Neurol 2011; 10: 530–537.

92.

Dua

Romanelli

Upchurch

Jr . Predictors of poor outcome after carotid intervention. J Vasc Surg 2016; 64: 663–670.

93.

Appelros

Stegmayr

Terent

. A review on sex differences in stroke treatment and outcome. Acta Neurol Scand 2010; 121: 359–369.

94.

Holroyd-Leduc

Kapral

Austin

. Sex differences and similarities in the management and outcome of stroke patients. Stroke 2000; 31: 1833–1837.

95.

Berger

Roncaglioni

Avanzini

. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306–313.

96.

Bailey

Scantlebury

Smyth

. Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol 2009; 29: 284–288.

97.

Rangel-Castilla

Snyder

Siddiqui

. Endovascular intracranial treatment of acute ischemic strokes. J Cardiovasc Surg (Torino) 2016; 57: 36–47.

98.

Reed

Cramer

Blough

. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32: 1832–1840.

99.

Deng

Reeves

Jacobs

. IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry. Neurology 2006; 66: 306–312.

100.

Hagberg

Wilson

Matsushita

. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 2004; 90: 1068–1075.

101.

Liu

. Sex differences in caspase activation after stroke. Stroke 2009; 40: 1842–1848.

102.

Selvamani

Sathyan

Miranda

. An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS One 2012; 7: e32662.

103.

Gall

Donnan

Dewey

. Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology 2010; 74: 975–981.

104.

Arboix

Oliveres

Garcia-Eroles

. Acute cerebrovascular disease in women. Eur Neurol 2001; 45: 199–205.

105.

Persky

Turtzo

McCullough

. Stroke in women: Disparities and outcomes. Curr Cardiol Rep 2010; 12: 6–13.

106.

Poynter

Shuman

Diaz-Granados

. Sex differences in the prevalence of post-stroke depression: A systematic review. Psychosomatics 2009; 50: 563–569.

107.

Jorge

Robinson

Arndt

. Mortality and poststroke depression: A placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160: 1823–1829.

108.

Pohjasvaara

Vataja

Leppavuori

. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001; 8: 315–319.

109.

Lenzi

Altieri

Maestrini

. Post-stroke depression. Rev Neurol (Paris) 2008; 164: 837–840.

110.

Petrea

Beiser

Seshadri

. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009; 40: 1032–1037.

111.

Barrett

Brott

Brown

Jr . Sex differences in stroke severity, symptoms, and deficits after first-ever ischemic stroke. J Stroke Cerebrovasc Dis 2007; 16: 34–39.